Retatrutide

Eli Lilly's chief executive said the company's future has 'never been brighter' as it positions retatrutide, its experimental weight-loss and diabetes drug, as the next major growth driver. The statement follows strong investor interest in Lilly's obesity pipeline, which already includes the blockbuster tirzepatide. Retatrutide is in late-stage trials and is viewed as a potential rival to next-generation obesity treatments. Markets are watching closely as competition in the weight-loss drug market intensifies with Novo Nordisk and others.